Adv. Sci. 2019, 7, 1901872
The last paragraph in Section 3 (page 8 of 43) of this article contained some inaccurate information. The corrected text is found here.
The sentence starting on line 3 is corrected as follows:
Omadacycline was approved by the FDA in 2018 for adult patients with community‐acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible microorganisms, including certain Enterobacteriaceae species.[94]
The sentence starting on line 11 is corrected as follows:
The antibiotic is more active than doxycycline against Enterococcus, including vancomycin‐resistant E. faecalis or E. faecium, and clinical S. aureus strains including methicillin‐resistant and tetracycline‐resistant strains.[98]
Reference [98] is corrected as follows:
a) A. B. Macone, B. K. Caruso, R. G. Leahy, J. Donatelli, S. Weir, M. P. Draper, S. K. Tanaka, S. B. Levy, Antimicrob. Agents Chemother. 2014, 58, 1127; b) A. C. Fluit, S. van Gorkum, J. Vlooswijk, Diagn. Microbiol. Infect. Dis. 2019, 94, 78.
The authors apologize for any misunderstanding this error may have caused.